Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II

Sean I. Savitz, Michael Chopp, Robert Deans, S. T. Carmichael, Donald Phinney, Larry Wechsler, Jaraslow Aronowski, Martin Bednar, Johannes Boltze, Cesar Borlongan, Thomas Chase, Dale Corbett, Charles S. Cox, Steven Cramer, Steven Fischkoff, Joseph Frank, David Greenberg, David Hess, Klaudyne Hong, Minako Koga & 15 others Theresa Jones, Armand Keating, Zaal Kokaia, Robert Mays, Keita Mora, Mark Pittenger, Paul Sanberg, Tim Schallert, John Sinden, Evan Snyder, Gary Steinberg, Steven Victor, Alison Willing, Ernest Yankee, Dileep R Yavagal

Research output: Contribution to journalReview article

172 Citations (Scopus)

Abstract

Cell-based therapies represent a new therapeutic approach for stroke. In 2007, investigators from academia, industry leaders, and members of the National Institutes of Health crafted recommendations to facilitate the translational development of cellular therapies as a novel, emerging modality for stroke from animal studies to clinical trials. This meeting was called Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) and was modeled on the format of the Stroke Therapy Academic Industry Roundtable (STAIR) meetings. Since publication of the original STEPS guidelines, there has been an explosive growth in the number of cellular products and in the number of new laboratory discoveries that impact the safety and potential efficacy of cell therapies for stroke. Any successful development of a cell product will need to take into consideration several factors, including the preclinical safety and efficacy profile, cell characterization, delivery route, in vivo biodistribution, and mechanism of action. In 2010, a second meeting called STEPS 2 was held to bring together clinical and basic science researchers with industry, regulatory, and National Institutes of Health representatives. At this meeting, participants identified critical gaps in knowledge and research areas that require further studies, updated prior guidelines, and drafted new recommendations to create a framework to guide future investigations in cell-based therapies for stroke.

Original languageEnglish (US)
Pages (from-to)825-829
Number of pages5
JournalStroke
Volume42
Issue number3
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Stroke
Industry
National Institutes of Health (U.S.)
Research Personnel
Guidelines
Safety
Publications
Therapeutics
Clinical Trials
Growth
Research

Keywords

  • cell therapy
  • guidelines
  • stem cells
  • stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Savitz, S. I., Chopp, M., Deans, R., Carmichael, S. T., Phinney, D., Wechsler, L., ... Yavagal, D. R. (2011). Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke, 42(3), 825-829. https://doi.org/10.1161/STROKEAHA.110.601914

Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. / Savitz, Sean I.; Chopp, Michael; Deans, Robert; Carmichael, S. T.; Phinney, Donald; Wechsler, Larry; Aronowski, Jaraslow; Bednar, Martin; Boltze, Johannes; Borlongan, Cesar; Chase, Thomas; Corbett, Dale; Cox, Charles S.; Cramer, Steven; Fischkoff, Steven; Frank, Joseph; Greenberg, David; Hess, David; Hong, Klaudyne; Koga, Minako; Jones, Theresa; Keating, Armand; Kokaia, Zaal; Mays, Robert; Mora, Keita; Pittenger, Mark; Sanberg, Paul; Schallert, Tim; Sinden, John; Snyder, Evan; Steinberg, Gary; Victor, Steven; Willing, Alison; Yankee, Ernest; Yavagal, Dileep R.

In: Stroke, Vol. 42, No. 3, 01.03.2011, p. 825-829.

Research output: Contribution to journalReview article

Savitz, SI, Chopp, M, Deans, R, Carmichael, ST, Phinney, D, Wechsler, L, Aronowski, J, Bednar, M, Boltze, J, Borlongan, C, Chase, T, Corbett, D, Cox, CS, Cramer, S, Fischkoff, S, Frank, J, Greenberg, D, Hess, D, Hong, K, Koga, M, Jones, T, Keating, A, Kokaia, Z, Mays, R, Mora, K, Pittenger, M, Sanberg, P, Schallert, T, Sinden, J, Snyder, E, Steinberg, G, Victor, S, Willing, A, Yankee, E & Yavagal, DR 2011, 'Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II', Stroke, vol. 42, no. 3, pp. 825-829. https://doi.org/10.1161/STROKEAHA.110.601914
Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L et al. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke. 2011 Mar 1;42(3):825-829. https://doi.org/10.1161/STROKEAHA.110.601914
Savitz, Sean I. ; Chopp, Michael ; Deans, Robert ; Carmichael, S. T. ; Phinney, Donald ; Wechsler, Larry ; Aronowski, Jaraslow ; Bednar, Martin ; Boltze, Johannes ; Borlongan, Cesar ; Chase, Thomas ; Corbett, Dale ; Cox, Charles S. ; Cramer, Steven ; Fischkoff, Steven ; Frank, Joseph ; Greenberg, David ; Hess, David ; Hong, Klaudyne ; Koga, Minako ; Jones, Theresa ; Keating, Armand ; Kokaia, Zaal ; Mays, Robert ; Mora, Keita ; Pittenger, Mark ; Sanberg, Paul ; Schallert, Tim ; Sinden, John ; Snyder, Evan ; Steinberg, Gary ; Victor, Steven ; Willing, Alison ; Yankee, Ernest ; Yavagal, Dileep R. / Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. In: Stroke. 2011 ; Vol. 42, No. 3. pp. 825-829.
@article{2709163a4df04e07ac64ae6c769a7727,
title = "Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II",
abstract = "Cell-based therapies represent a new therapeutic approach for stroke. In 2007, investigators from academia, industry leaders, and members of the National Institutes of Health crafted recommendations to facilitate the translational development of cellular therapies as a novel, emerging modality for stroke from animal studies to clinical trials. This meeting was called Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) and was modeled on the format of the Stroke Therapy Academic Industry Roundtable (STAIR) meetings. Since publication of the original STEPS guidelines, there has been an explosive growth in the number of cellular products and in the number of new laboratory discoveries that impact the safety and potential efficacy of cell therapies for stroke. Any successful development of a cell product will need to take into consideration several factors, including the preclinical safety and efficacy profile, cell characterization, delivery route, in vivo biodistribution, and mechanism of action. In 2010, a second meeting called STEPS 2 was held to bring together clinical and basic science researchers with industry, regulatory, and National Institutes of Health representatives. At this meeting, participants identified critical gaps in knowledge and research areas that require further studies, updated prior guidelines, and drafted new recommendations to create a framework to guide future investigations in cell-based therapies for stroke.",
keywords = "cell therapy, guidelines, stem cells, stroke",
author = "Savitz, {Sean I.} and Michael Chopp and Robert Deans and Carmichael, {S. T.} and Donald Phinney and Larry Wechsler and Jaraslow Aronowski and Martin Bednar and Johannes Boltze and Cesar Borlongan and Thomas Chase and Dale Corbett and Cox, {Charles S.} and Steven Cramer and Steven Fischkoff and Joseph Frank and David Greenberg and David Hess and Klaudyne Hong and Minako Koga and Theresa Jones and Armand Keating and Zaal Kokaia and Robert Mays and Keita Mora and Mark Pittenger and Paul Sanberg and Tim Schallert and John Sinden and Evan Snyder and Gary Steinberg and Steven Victor and Alison Willing and Ernest Yankee and Yavagal, {Dileep R}",
year = "2011",
month = "3",
day = "1",
doi = "10.1161/STROKEAHA.110.601914",
language = "English (US)",
volume = "42",
pages = "825--829",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II

AU - Savitz, Sean I.

AU - Chopp, Michael

AU - Deans, Robert

AU - Carmichael, S. T.

AU - Phinney, Donald

AU - Wechsler, Larry

AU - Aronowski, Jaraslow

AU - Bednar, Martin

AU - Boltze, Johannes

AU - Borlongan, Cesar

AU - Chase, Thomas

AU - Corbett, Dale

AU - Cox, Charles S.

AU - Cramer, Steven

AU - Fischkoff, Steven

AU - Frank, Joseph

AU - Greenberg, David

AU - Hess, David

AU - Hong, Klaudyne

AU - Koga, Minako

AU - Jones, Theresa

AU - Keating, Armand

AU - Kokaia, Zaal

AU - Mays, Robert

AU - Mora, Keita

AU - Pittenger, Mark

AU - Sanberg, Paul

AU - Schallert, Tim

AU - Sinden, John

AU - Snyder, Evan

AU - Steinberg, Gary

AU - Victor, Steven

AU - Willing, Alison

AU - Yankee, Ernest

AU - Yavagal, Dileep R

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Cell-based therapies represent a new therapeutic approach for stroke. In 2007, investigators from academia, industry leaders, and members of the National Institutes of Health crafted recommendations to facilitate the translational development of cellular therapies as a novel, emerging modality for stroke from animal studies to clinical trials. This meeting was called Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) and was modeled on the format of the Stroke Therapy Academic Industry Roundtable (STAIR) meetings. Since publication of the original STEPS guidelines, there has been an explosive growth in the number of cellular products and in the number of new laboratory discoveries that impact the safety and potential efficacy of cell therapies for stroke. Any successful development of a cell product will need to take into consideration several factors, including the preclinical safety and efficacy profile, cell characterization, delivery route, in vivo biodistribution, and mechanism of action. In 2010, a second meeting called STEPS 2 was held to bring together clinical and basic science researchers with industry, regulatory, and National Institutes of Health representatives. At this meeting, participants identified critical gaps in knowledge and research areas that require further studies, updated prior guidelines, and drafted new recommendations to create a framework to guide future investigations in cell-based therapies for stroke.

AB - Cell-based therapies represent a new therapeutic approach for stroke. In 2007, investigators from academia, industry leaders, and members of the National Institutes of Health crafted recommendations to facilitate the translational development of cellular therapies as a novel, emerging modality for stroke from animal studies to clinical trials. This meeting was called Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) and was modeled on the format of the Stroke Therapy Academic Industry Roundtable (STAIR) meetings. Since publication of the original STEPS guidelines, there has been an explosive growth in the number of cellular products and in the number of new laboratory discoveries that impact the safety and potential efficacy of cell therapies for stroke. Any successful development of a cell product will need to take into consideration several factors, including the preclinical safety and efficacy profile, cell characterization, delivery route, in vivo biodistribution, and mechanism of action. In 2010, a second meeting called STEPS 2 was held to bring together clinical and basic science researchers with industry, regulatory, and National Institutes of Health representatives. At this meeting, participants identified critical gaps in knowledge and research areas that require further studies, updated prior guidelines, and drafted new recommendations to create a framework to guide future investigations in cell-based therapies for stroke.

KW - cell therapy

KW - guidelines

KW - stem cells

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=79952072156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952072156&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.110.601914

DO - 10.1161/STROKEAHA.110.601914

M3 - Review article

VL - 42

SP - 825

EP - 829

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 3

ER -